Comparative Pharmacology
Head-to-head clinical analysis: ENOXAPARIN SODIUM PRESERVATIVE FREE versus LOVENOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOXAPARIN SODIUM PRESERVATIVE FREE versus LOVENOX.
ENOXAPARIN SODIUM (PRESERVATIVE FREE) vs LOVENOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enoxaparin binds to antithrombin III (ATIII), accelerating its inhibition of coagulation factors Xa and IIa (thrombin). Its anti-factor Xa to anti-factor IIa activity ratio is approximately 3.6:1.
Low molecular weight heparin (LMWH) that binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin, thereby preventing thrombus formation.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily. For prophylaxis: 40 mg subcutaneously once daily or 30 mg subcutaneously every 12 hours.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis in abdominal surgery, hip or knee replacement; 30 mg subcutaneously every 12 hours for prophylaxis in medical patients; 0.5 mg/kg subcutaneously once daily for prophylaxis in patients with acute coronary syndrome.
None Documented
None Documented
Terminal elimination half-life is 4.5 hours after subcutaneous administration based on anti-Factor Xa activity; prolonged to 6-7 hours in renal impairment (CrCl <30 mL/min).
Terminal half-life: 4.5-7 hours after subcutaneous administration; prolonged in renal impairment (up to 16 hours with CrCl <30 mL/min), requiring dose adjustment.
Renal excretion of anti-Factor Xa activity accounts for approximately 40% of total clearance; a small fraction undergoes biliary/fecal elimination (<10%).
Renal: 40-60% as active and inactive fragments via glomerular filtration and tubular secretion; biliary/fecal: minimal, <10%.
Category A/B
Category C
Low Molecular Weight Heparin
Low Molecular Weight Heparin